1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

Peloton Therapeutics, Inc.

Have updates for this profile?  Please contribute data

About
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2011

Location

Dallas TX US

Primary Industry

Biotechnology

About

Founded 2011 and based in Texas, US, Peloton Therapeutics, Inc. is a biotechnology company engaged in early-stage cancer pharmaceutical discovery for hypoxia-inducible factor-2a, a transcription factor that regulates the body’s response to diminished availability of oxygen. They develop the PT2977, a potent, selective, oral HIF-2a inhibitor for the treatment of kidney cancer, specifically metastatic RCC (mRCC) and VHL disease-associated RCC.
Current Investors
Cancer Prevention & Research Institute of Texas, The Column Group, Topspin Partners

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.pelotontherapeutics.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo